Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets tough lymphomas in early trial

NCT ID NCT07069699

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase trial tests a drug called pidnarulex (CX-5461) in about 50 people with aggressive B-cell lymphomas that have not responded to standard treatments. The goal is to find the best dose and check if the drug is safe and can shrink tumors. Participants will also have biopsies and scans to see how the drug affects their cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pidnarulex (CX-5461)
What this could lead to
If it works, this could offer a new treatment option for people with aggressive B-cell lymphomas that have not responded to prior therapies.
What could go wrong
This is an early-phase trial with only 50 participants, so it is too soon to know if the drug is effective. Side effects are still being studied, and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Burkitt lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BURKITT LYMPHOMA DOUBLE-EXPRESSOR LYMPHOMA HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS

Contacts and locations

Locations

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Kansas Cancer Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • University of Kansas Clinical Research Center

    RECRUITING

    Fairway, Kansas, 66205, United States

  • University of Kansas Hospital-Indian Creek Campus

    RECRUITING

    Overland Park, Kansas, 66211, United States

  • University of Kansas Hospital-Westwood Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.